e currency trading- Top Featured snippets

The Nikkei 225 index closed at 39,881.10 points in early trading, up 1.29%.The next "explosion point" of biomedicine may appear in Shenzhen. "China's pharmaceutical innovation ranks first in the second echelon in the world in terms of the quantitative indicators of R&D pipelines and listed new drugs." A few days ago, Song Ruilin, executive president of China Pharmaceutical Innovation Promotion Association, held the "Star of the Bay Area" biomedical source innovation conference in Shenzhen, and believed that China's pharmaceutical research and industrial development were entering a new stage of innovation. Chen Qiyu, vice president of China Pharmaceutical Innovation Promotion Association and executive director and co-CEO of Fosun International, said that Shenzhen has great advantages and development momentum in linking Greater Bay Area's urban development and AI technology. By leveraging the resources in the Bay Area and making good use of these advantages, it is possible to find a new fulcrum in the future biomedical R&D innovation track, and the next "explosion point" of biomedicine is likely to appear in Shenzhen.Shanghai's state-owned assets reform index rose, with the daily limit of First Medicine, Yimin Group, Kaikai Industry and Shanghai Phoenix, and Shanghai 900 rose by more than 8%.

The securities sector fluctuated and strengthened, and the securities sector fluctuated and strengthened. Guosheng Financial Holdings had three consecutive boards, Guolian Securities rose more than 8%, and Harbin Investment Co., Ltd., Huaxin Co., Ltd., Cinda Securities and Southwest Securities followed suit.Beijing Haidian Joy City will open on December 21st. According to WeChat official account news of "Beijing Haidian" WeChat, Haidian Joy City, the fourth joy city in Beijing, will open on December 21st. At present, many brands have come to an end, and the merchants in the venue have entered the preparations for opening. It is understood that Haidian Joy City is expected to introduce more than 280 brands.Treasury futures rose by 0.30%, the 30-year main contract rose by 0.30%, and the 30-year main contract rose by 0.30%, a record high. The 10-year main contract rose by 0.12%, the 5-year main contract rose by 0.05% and the 2-year main contract rose by 0.02%.

The next "explosion point" of biomedicine may appear in Shenzhen. "China's pharmaceutical innovation ranks first in the second echelon in the world in terms of the quantitative indicators of R&D pipelines and listed new drugs." A few days ago, Song Ruilin, executive president of China Pharmaceutical Innovation Promotion Association, held the "Star of the Bay Area" biomedical source innovation conference in Shenzhen, and believed that China's pharmaceutical research and industrial development were entering a new stage of innovation. Chen Qiyu, vice president of China Pharmaceutical Innovation Promotion Association and executive director and co-CEO of Fosun International, said that Shenzhen has great advantages and development momentum in linking Greater Bay Area's urban development and AI technology. By leveraging the resources in the Bay Area and making good use of these advantages, it is possible to find a new fulcrum in the future biomedical R&D innovation track, and the next "explosion point" of biomedicine is likely to appear in Shenzhen.Baijiayun received $15 million in financing. One-stop AI video technology service provider Baijiayun (NASDAQ：RTC) announced that the company had signed a series of important agreements with YA II PN, Ltd, a fund managed by Yorkville Advisors Global and LP. The company received $15 million in financing, and the down payment of $3 million was received on the signing date of the agreement.China Petroleum and others set up a joint exploration company in Xinjiang with a registered capital of 1 billion yuan. According to the enterprise search APP, PetroChina Tayou Joint Exploration (Xinjiang) Co., Ltd. was recently established, with the legal representative of Liu Weibo and a registered capital of 1 billion yuan. Its business scope includes: mineral resources exploration. Enterprise survey shows that the company is jointly owned by PetroChina Taihu (Beijing) Investment Co., Ltd., a wholly-owned subsidiary of China Petroleum, and Xinjiang Yaxin CBM Investment and Development (Group) Co., Ltd.